RecruitingPhase 2NCT06923072

Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement

Studying Atrophic papulosis

Last synced from ClinicalTrials.gov May 4, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Cornelia D Cudrici, M.D., M.D
National Heart, Lung, and Blood Institute (NHLBI)
Intervention: Baricitinib(drug)
Enrollment: 12 enrolled
Eligibility: 18-99 years · All sexes
Timeline: 2026 – 2030

Study locations (1)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06923072 on ClinicalTrials.gov

← Back to all trials